Track topics on Twitter Track topics that are important to you
]]>(MedPage Today) -- The JAK-1 inhibitor upadacitinib (Rinvoq) was superior to placebo in inducing endoscopic remission in refractory Crohn's disease (CD) patients, the phase II randomized CELEST trial showed. Julián Panés, MD, PhD, of...
Original Article: JAK1 Inhibitor Promising for Refractory Crohn'sNEXT ARTICLE
Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system. Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...